20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Olema Pharmaceuticals Inc (OLMA) operates in the BIOTECHNOLOGY industry and is headquartered in San Francisco, United States with about 150 employees. Its market capitalization is roughly $859 million. In the fiscal year ended 2025-12-31, OLMA reported $0M in revenue and ($162M) in net income.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $0M | $0M | ($2M) | ($2M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($221M) | ($179M) | ($142M) | ($105M) | ($107M) | ($71M) | ($22M) | ($4M) | ($2M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — |
| Net Income | ($205M) | ($162M) | ($129M) | ($97M) | ($103M) | ($71M) | ($22M) | ($4M) | ($2M) |
| Net Margin % | — | — | — | — | — | — | — | — | — |
| EBITDA | ($204M) | ($162M) | ($129M) | ($96M) | ($107M) | ($71M) | ($22M) | ($4M) | ($2M) |
| Earnings Per Share (EPS) | $-2.12 | $-1.87 | $-2.20 | $-2.14 | $-2.56 | $-1.80 | $-0.56 | $-0.11 | $-0.16 |
| Shares Outstanding (M) | 104M | 87M | 59M | 45M | 40M | 40M | 39M | 40M | 14M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | — | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($67M) | ($58M) | ($50M) | ($46M) | ($48M) | ($35M) | ($37M) | ($38M) |
| Operating Margin % | — | — | — | — | — | — | -10101.1% | — |
| Net Income | ($63M) | ($53M) | ($46M) | ($42M) | ($44M) | ($30M) | ($34M) | ($35M) |
| Net Margin % | — | — | — | — | — | — | -9221.7% | — |
| EBITDA | ($63M) | ($53M) | ($46M) | ($42M) | ($44M) | ($30M) | ($33M) | ($34M) |
| Earnings Per Share (EPS) | $-0.61 | $-0.52 | $-0.50 | $-0.49 | $-0.51 | $-0.36 | $-0.57 | $-0.60 |
| Shares Outstanding (M) | 104M | 103M | 91M | 86M | 85M | 85M | 59M | 57M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($165M) | ($147M) | ($104M) | ($84M) | ($82M) | ($51M) | ($20M) | ($3M) | ($2M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $2M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($165M) | ($147M) | ($105M) | ($84M) | ($82M) | ($52M) | ($20M) | ($3M) | ($2M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | $3M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($46M) | ($46M) | ($38M) | ($35M) | ($30M) | ($44M) | ($26M) | ($27M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($46M) | ($46M) | ($38M) | ($35M) | ($30M) | ($44M) | ($26M) | ($27M) |
| FCF Margin % | — | — | — | — | — | — | -7220.9% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $487M | $533M | $451M | $277M | $216M | $296M | $343M | $0M | $3M |
| Cash & Cash Equivalents | $49M | $48M | $139M | $69M | $24M | $14M | $339M | $0M | $3M |
| Total Liabilities | $56M | $55M | $42M | $23M | $18M | $11M | $5M | $11M | $10M |
| Total Debt (Short + Long-Term) | $4M | $4M | $1M | $1M | $1M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $431M | $479M | $409M | $254M | $198M | $285M | $338M | ($11M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OLMA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms